Haiwen Ni
YOU?
Author Swipe
View article: Comparative analysis of once-weekly versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma: a meta-analysis
Comparative analysis of once-weekly versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma: a meta-analysis Open
Background: While carfilzomib has shown effectiveness in treating relapsed or refractory multiple myeloma (RRMM), the best frequency of dosing is still debated. This meta-analysis aims to investigate the differences in safety and effective…
View article: Profiling adaptive immunity: A quantitative framework for immune repertoire dynamics and clinical diagnostics
Profiling adaptive immunity: A quantitative framework for immune repertoire dynamics and clinical diagnostics Open
View article: Luteolin inhibits diffuse large B-cell lymphoma cell growth through the JAK2/STAT3 signaling pathway
Luteolin inhibits diffuse large B-cell lymphoma cell growth through the JAK2/STAT3 signaling pathway Open
Luteolin, a flavonoid present in botanical drugs, plants, and dietary sources, has demonstrated anticancer properties against various tumors, yet its role in diffuse large B-cell lymphoma (DLBCL) remains unclear. This study aimed to uncove…
View article: Clinicopathological characteristics, prognostic factors, and outcomes of elderly patients with lymphoma‐associated hemophagocytic lymphohistiocytosis: A multicenter analysis
Clinicopathological characteristics, prognostic factors, and outcomes of elderly patients with lymphoma‐associated hemophagocytic lymphohistiocytosis: A multicenter analysis Open
Background Lymphoma is the most common secondary cause of hemophagocytic lymphohistiocytosis (HLH) in adults. Lymphoma‐associated HLH (LA‐HLH) in the elderly population is not rare, however, little has been reported regarding clinicopathol…
View article: Energy-Based Systematic Modeling of Adaptive Immune Repertoire Behavior: Study on Cell Proliferation & Somatic Hypermutation process
Energy-Based Systematic Modeling of Adaptive Immune Repertoire Behavior: Study on Cell Proliferation & Somatic Hypermutation process Open
Monitoring and describing the adaptive immune repertoire(IR) for disease detection and diagnosis is essential in healthcare research. Many phenomenon have been observed to generalize the static property of IR, but the mathematical descript…
View article: Supplementary Figure Legends from Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191
Supplementary Figure Legends from Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191 Open
Supplementary Figure Legends
View article: Supplementary Figures from Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191
Supplementary Figures from Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191 Open
Supplementary Figure 1. BCWM. 1 (upper panel) and MWCL-1 cells (lower panel) were seeded in 96-well plates (20,000 cells/well) and treated with increasing concentrations (0.0, 0.15, 0.3125, 0.625, 1.25, 2.5, 5.0 ï�M) of the indicated IRAK…
View article: Supplementary Figures from Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191
Supplementary Figures from Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191 Open
Supplementary Figure 1. BCWM. 1 (upper panel) and MWCL-1 cells (lower panel) were seeded in 96-well plates (20,000 cells/well) and treated with increasing concentrations (0.0, 0.15, 0.3125, 0.625, 1.25, 2.5, 5.0 ï�M) of the indicated IRAK…
View article: Supplementary Tables from Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191
Supplementary Tables from Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191 Open
Supplementary Table 1. Gene set enrichment analysis* of the impact of exposing Waldenström's cell lines to R191 with a focus on Akt. Supplementary Table 2. Combination index analysis of R191-based regimens in cell line models of Waldenstr…
View article: Data from Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191
Data from Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191 Open
Purpose:Waldenström's macroglobulinemia is an incurable lymphoproliferative disorder driven by an L265P mutation in the myeloid differentiation primary response gene 88 (MYD88), which activates downstream NF-κB signaling through the…
View article: Supplementary Figure Legends from Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191
Supplementary Figure Legends from Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191 Open
Supplementary Figure Legends
View article: Supplementary Tables from Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191
Supplementary Tables from Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191 Open
Supplementary Table 1. Gene set enrichment analysis* of the impact of exposing Waldenström's cell lines to R191 with a focus on Akt. Supplementary Table 2. Combination index analysis of R191-based regimens in cell line models of Waldenstr…
View article: Data from Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191
Data from Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191 Open
Purpose:Waldenström's macroglobulinemia is an incurable lymphoproliferative disorder driven by an L265P mutation in the myeloid differentiation primary response gene 88 (MYD88), which activates downstream NF-κB signaling through the…
View article: Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191
Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191 Open
Purpose: Waldenström's macroglobulinemia is an incurable lymphoproliferative disorder driven by an L265P mutation in the myeloid differentiation primary response gene 88 (MYD88), which activates downstream NF-κB signaling through the Myddo…
View article: Guillain Barré Syndrome in a multiple myeloma patient after the first course of bortezomib therapy: A case report
Guillain Barré Syndrome in a multiple myeloma patient after the first course of bortezomib therapy: A case report Open
Bortezomib is approved for treating relapsed multiple myeloma (MM) and mantle cell lymphoma, and clinical evidence has shown complete clinical responses in MM patients. Peripheral neuropathy is one of the most common adverse effects of bor…